|
The International
Journal of Artificial Organs / Vol. 26 / no. 4, 2003 / pp. 297-303
Artificial Kidney and
Dialysis
L. TYLICKI
1, T. NIEWEGLOWSKI 1, B. BIEDUNKIEWICZ 1,
A. CHAMIENIA 1, A. DEBSKA-SLIZIEN 1,
E. ALEKSANDROWICZ
2, W. LYSIAK-SZYDLOWSKA 2, B.
RUTKOWSKI 1
1
Department of Nephrology, Transplantology and Internal Medicine
2
Department of
Clinical Nutrition and Diagnostic Laboratory, Medical University of Gdansk, Gdansk -
Poland
ABSTRACT: Ozonated autohemotherapy is used as a complementary
medical approach in the treatment of vascular disorders. One of the greatest problems
concerning an application of ozone in medicine is its induction of oxidative stress. The
standards of ozonotherapy were elaborated recently making this treatment useful and
probably non toxic. The aim of the present study was to investigate the influence of
ozonated autohemotherapy on the oxidative stress extent in hemodialyzed patients, known to
be particularly exposed to generation and deleterious effects of free radicals. Twelve
continuously hemodialyzed subjects with atherosclerotic ischemia of the lower limbs were
examined in a prospective, controlled, single blind study. Autohemotherapy with blood
exposure to oxygen served as a control. The protein and lipid peroxidation
products, the
reduced glutathione level in red blood cells and free hemoglobin plasma concentration were
measured. The study showed that ozonated autohemotherapy with ozone concentration 50
µg/ml per gram of blood induced a significant decrease in glutathione level after 9
sessions of this procedure. Therapy did not cause either the enhancement of protein and
lipid peroxidation, or erythrocytes damage. It seems likely that the antioxidant defense
system, part of which is glutathione, neutralizes oxidative properties of ozone in this
concentration and protects against oxidative cell damage. (Int J Artif Organs 2003; 26:
297- 303)
KEY
WORDS: Ozone, Autohemotherapy, Atherosclerosis, Hemodialysis, Renal failure, Oxidative stress, Free
radicals, Hemolysis
INTRODUCTION
Ozonotherapy as a complementary medical approach has been known for more
than 50 years. There are some areas where this kind of treatment may be useful
nowadays,
e.g. resistant infectious diseases, immune deficiency syndromes, degenerative diseases of
the central nervous system, orthopedic pathologies and vascular disorders. Over the last
decade standards of ozone use in medicine were elaborated making this therapy useful and
probably safe. The precise control of applied ozone dosage seems to play a critical
role.
The route of ozone administration defined as ozonated autohemotherapy (O3-AHT) is most
commonly used and consists of the ex vivo sterile exposure of a known blood volume
to an equivalent volume of oxygen-ozone mixture with strictly established ozone
concentration (1). Patients with end-stage renal disease (ESRD) on maintenance renal
replacement therapy are particularly exposed to the development of atherosclerosis (2).
Many of them manifest coronary heart disease or atherosclerotic ischemia of lower limbs
(AILL). Several reports have indicated that treatment with ozone was useful in the therapy
of AILL (3, 4). The mechanisms involved in the beneficial activity of this therapy, lead
to the improvement of blood flow in hypoxic areas and the attenuation of ischemic symptoms
(4). One of the greatest problems concerning ozonotherapy is its potential
toxicity. Ozone
is known as a highly reactive oxidant that in inhalatory form may be hazardous to the
respiratory system (5). Oxidative injury has been considered as one of the possible side
effects of O3-AHT since the role of oxidative stress has been proven in the pathogenesis
of many disorders (6, 7). It is obvious that ozone in contact with blood can induce the
generation of reactive oxygen species (ROS) (8). However, this effect is detrimental only
when high a concentration of ozone is used or in a case of a severely impaired antioxidant
defense system (1). The safe range of ozone concentrations in O3-AHT is currently known
(1). ROS generation during O3-AHT, applied in dosages from this range, is believed to be
almost completely quenched by multifactorial antioxidant systems present in plasma and
blood cells (1, 8). The recommendations concerning ozone dosage are based on the studies
and therapeutic experience derived from the treatment of subjects with preserved renal
function. This problem has not yet been studied in hemodialyzed (HD) patients, who have an
impaired antioxidant system and therefore are particularly threatened by deleterious
effects of free radicals (9). In this context the safety of O3-AHT, a therapeutic
intervention with a potential to generate ROS is of particular importance. We performed a
prospective, controlled, single blind study to find whether O3-AHT causes oxidative stress
in patients with ESRD treated chronically with HD. Effects of O3-AHT, applied in the
therapeutic dose of ozone - 50µg/ml on the level of lipid and protein
peroxidation, the
extent of red blood cell hemolysis and the reduced glutathione (GSH) concentration in red
blood cells were determined.
MATERIALS AND METHODS
Subjects
The group of patients
comprised 12 subjects (8 male, 4 female), aged 64.8±7.6 (range 50-75) years with ESRD
treated with hemodialysis. Diabetic nephropathy was diagnosed as primary renal disease and
cause of renal replacement therapy in 3 patients, polycystic kidney disease in 5 and
chronic glomerulonephritis in one. In four remaining individuals the cause of ESRD was not
established. All patients underwent regular bicarbonate hemodialysis treatment, three
times per week for more than one year (average 4.5±3.1 years). Low-flux, polysulfone
dialysers were used in all subjects. All of them suffered from symptomatic AILL (stage
II-IV according to Fontain) which was the main reason for the implementation of
ozonotherapy. The hemodialysis prescription, namely dialyser type, HD session
length, rate
of dialysis solution and blood flows were unchanged during the study. Any permanent
pharmacological treatment known to influence redox status including hypotensive and
lipid-lowering therapy remained unchanged throughout the study. No new drugs were
administered. All patients received supplementation of vitamin C (400 mg/per
week) as an antioxidant. The individuals with active chronic inflammatory disease and with symptomatic
or asymptomatic (as confirmed by laboratory tests: Creactive protein evaluation) acute
infection were excluded from the study.
Study design
At the beginning subjects received 9 sessions of autohemotherapy connected
with the blood exposure to medical oxygen (AHT) as a control, followed by 9 sessions of
autohemotherapy connected with exposure to ozone O3-AHT). Procedures were performed three
times a week in the early morning, just before the hemodialysis session in a single blind
manner. Ozone generator (ATO-3, Kriometrum, Warsaw, Poland) attested by the Polish Health
Ministry was used in the study. The procedure was as follows: 250 ml of patient blood was
drawn into a sterile, transparent, glass bottle. Sodium citrate was used as an
anticoagulant. The bottle was then connected to the ozone generator and this way blood was
exposed to gas: medical oxygen in the control part of the study and oxygen-ozone mixture
during the O3-AHT. Gas was applied in four programmed cycles which lasted altogether 5
minutes. There was a precisely measured volume of gas, equal to the blood volume (1 to 1
relationship). In order to avoid blood foaming, bottle was continuously and gently
shaken. Afterwards, the blood was slowly reinfused into the donor via arterio-venous dialysis
needle. During O3-AHT sessions blood was exposed to oxygen-ozone mixture with ozone
concentration of 50 µg/ml per gram of blood. The markers of lipid peroxidation (plasma
levels of malonaldehyde and 4-hydroxyalkenals) (LPO), the marker of protein peroxidation
(plasma level of carbonyl groups) (PP), the level of reduced glutathione in red blood
cells (GSH) and the plasma concentration of free hemoglobin (FHP) were measured. Three
blood samples were collected from all subjects at the following timepoints: before the
first session of AHT, after 9 sessions of AHT (control), and after 9 sessions of O3-AHT.
To evaluate the influence of the first exposure to ozone on the parameters
measured,
samples of blood were also withdrawn before and 20 minutes after the first session of
O3-AHT.
Biochemical analysis
LPO
- Samples of blood were collected in sterile EDTA tubes and
centrifuged at 2500 g for 10 min at 4°C. Afterwards, supernatant was carefully collected
and stored at -75°C until the assay. Samples were protected from light. Quantitive
analysis of lipid peroxidation in the plasma was performed by colorimetric assay according
to Esterbauer (10) using a commercially available kit (LPO- 586, Oxis, Portland).
Briefly,
measurement was based on the reaction of chromogenic reagent, N-methyl-2- phenylindole
with malonaldehyde and 4-hydroxyalkenals, products of polyunsaturated fatty acid
peroxidation. Reaction in the presence of the methanesulfonic acid was carried on for 60
minutes at 45° C. After centrifugation, absorbance was measured at 586 nm. All assays
were performed in duplicate.
GSH - The level of
reduced glutathione in red blood cells was measured colorimetricly using a commercial kit
(GSH-400, Oxis, Portland). Samples of blood were collected into heparinized
tubes. After 5
minutes centrifugation at 2500g at 4°C, erythrocyte pellet was stored at -70°C until
analysis, but no longer than 2 weeks. Analytical procedures were performed according to
kit producers recommendations. Briefly, the method was based on a chemical reaction
leading to formation of chromophoric thione. In the first step, reaction between all
mercaptans from the sample and 4-chloro-1-methyl-7- trifluromethyl-quinolinium
methylsulfate led to the formation of thioethers. The second step was ßelemination
reaction that took place under alkaline conditions, which specifically transformed
thioethers obtained from glutathion into a thione (11). After 10 min incubation at 25°C
absorbance was measured at 400 nm. Final results were expressed in micromoles GSH per gram
hemoglobin (Hb). Hemoglobin was determined spectrophotometrically. All analyses were
performed in duplicate.
PP -The level of
carbonyl groups was measured according to a method described by Garibaldi et al (12). The
method is based on a reaction of 2,4 - dinitrophenylhydrazine with carbonyl groups of
protein molecules. The product of this reaction was measured colometrically at 370
nm.
Results were expressed in nmol/mg of protein.
FHP
- The level of
plasma free hemoglobin wasanalysed according to the method described by Watkins that
utilizes fractional absorbance of oxyhemoglobin at 578 nm (13). Sample of blood was drawn
into the heparinized tubes. Immediately after plasma separation, FHP was measured
spectrophotometrically.
Statistics
Data are expressed as mean ± SD. Distribution of variables was evaluated
using Shapiro-Wilks test. Differences of variables measured more than twice were
assessed by analysis of variance for repeated measurements or Friedmans test;
otherwise by Students t-test for paired comparison or Wilcoxon test. Data were
evaluated using STATISTICA (version 5.1, StatSoft Inc.)
TABLE I -
DETAILED RESULTS OF THE STUDY
|
|
Start
of the study |
After
AHT (control) |
After
1st O3-AHT |
After
9th O3AHT |
GSH
µmol/g Hb |
12.37 ± 10.88
a b |
7.14 ± 4.87 b |
8.37 ± 9.33 b |
4.39 ± 1.55 a |
PP
nmol/mg protein |
3.90 ± 3.19 |
3.54 ± 2.45 |
3.61 ± 2.9 |
3.93 ± 2.27 |
FHP
mg/dl |
11.69 ± 6.39 |
10.97 ± 7.12 |
13.43 ± 7.25 |
11.15 ± 4.27 |
LPO
µmol/l |
1.34 ± 0.4 |
1.22 ± 0.39 |
1.32 ± 0.44 |
1.79 ± 1.53 |
a significant difference (p< 0.05): start level vs. level after 9 th
O3-AHT
b borderline significance difference (0.05<p< 0.1): start level vs.
level after AHT (control).
RESULTS
All twelve patients who entered the study completed the
protocol. Table I
shows detailed results of the study. GSH concentration in red blood cells after O3-AHT (9
sessions) was statistically lower (p<0.05) when compared to the baseline (-64.51%). GSH
concentration after AHT (control) was lower compared to baseline (-42.27%). Difference was
in the borderline range of significance (p< 0.07). LPO level after O3-AHT (9
sessions)
was higher by 33.6% compared to baseline and was not statistically significant. There were
no significant differences in PP level between 3 collections. FHP level did not change
during the study. GSH concentration in red blood cells, LPO plasma level, PP plasma level
and FHP concentration did not change after the first session of O3-AHT compared to the
levels before this procedure.
DISCUSSION
Free radicals and other ROS are physiologically formed in the human body.
Their generation may also result from exposure to toxic agents or from different disease
processes. Antioxidant defense includes enzymatic and nonenzymatic components that are in
balance with the generation of ROS. The imbalance in favor of the later is termed as
oxidative stress. The subsequent oxidative injury of lipids, proteins and DNA may lead to
serious cell damage (14). The prooxidative state of HD patients implies several factors
related to ESRD as well as HD procedure (9). Uremia, per se, is believed to cause
overproduction of ROS and impair the antioxidant system (15, 16). Hemoand
bioincompatibility of membranes and blood lines used in dialysis and the presence of trace
amounts of endotoxins and/or pyrogens in the dialysate play a critical role in the
production of ROS triggered by HD procedure (17, 18). Additionally, HD impairs the
antioxidant defense by losses of hydrophilic unbound small-molecular-weight substances and
trace elements such as vitamin C and selenium (19, 20). These abnormalities may be further
exacerbated in older or diabetic individuals, the group still growing among patients on
maintenance HD (21). There is no doubt that protection from the oxidative stress is of
particular importance in HD patients. Evidence showed that oxidative stress is involved in
several disease states, such as anemia, secondary amyloidosis and
atherosclerosis, the
major cause of mortality in this population (2, 7, 22-24). The authors demonstrated
previously that O3-AHT might attenuate clinical signs of lower limb ischemia in HD
patients with AILL. In a prospective controlled study, a significant prolongation in
intermittent claudication distance (by 30.5%) after O3-AHT was found (25). The question
remains, however, whether this therapy is safe when oxidative stress is
considered. Ozone
is known to be a strong oxidant. When dissolved in the blood, it produces a number of ROS.
A major part of ozone activity is inhibited by antioxidants but some react with
polyunsaturated fatty acids (PUFA) and generate hydrogen peroxide and lipid oxidation
products. The latter are postulated to be important messengers responsible for
transmitting both beneficial and toxic effects of ozone. A small part of ozone decomposes
directly to hydroxyl radical. Increased plasma level of hydrogen peroxide, a unionized
molecule, is immediately transferred into intracytoplasmic water. The intracellular
environment counteracts this potentially toxic process by quenching hydrogen peroxide with
GSH (1, 8, 26, 27). In the present study, a medium concentration of ozone in an
oxygen-ozone mixture (50 µg/ml) was used. According to Bocci (1), oxidative effects of
ozone are dose-dependent. The therapeutic window of ozone concentration for O3-AHT ranges
between 20-80 µg/ml (0.42-1.66 mmol/L). In the healthy population, oxidative properties
of ozone in dosages even up 100 µg/ml are almost completely handled by antioxidant forces
(8, 26). To examine the effects of O3-AHT on the antioxidant defense system, GSH
concentration in red blood cells was evaluated. GSH is an important nonenzymatic player in
the antioxidant defense and one of the first agents involved in the protection from
oxidative stress due to ozone exposure (14, 28, 29) GSH concentration decreased nearly by
65 % after 9 sessions of O3-AHT. This result is in line with previous reports that showed
increased consumption of GSH during O3-AHT (28, 30). Strikingly, the drop of GSH
store,
observed in the present study, was much higher than those reported in other studies
performed in individuals with normal renal function. Bocci at al (31) used ozone in
concentration even up to 80 µg/ml and found a decrease of GSH nohigher than 15%. In
another study, the total antioxidant status of blood, measured by the Rice-Evans
method,
decreased by 20% after exposure to 80 µg ozone/ml (32). It seems likely, that the high
consumption of GSH due to increased ROS generation in HD patients, enhanced by O3-AHT
achieved supremacy over the GSH regeneration process. It is noteworthy that a decrease in
the GSH level (42.27%, borderline significance) was also observed after control AHT among
exposure to oxygen, known not to cause induction of oxidative stress (32). Thus, it may be
suggested that some part of oxidative stimulation after O3- AHT may result not only from
ozone exposure per se but also from the procedures associated solely with the
autohemotherapy. It is well known that blood manipulation, contact of blood with drains
and exposure to the energy of light may be the factors which can induce ROS production
(33, 34). To examine whether this shift of the redox balance in favor of the prooxidative
state induced any serious injury, the levels of protein and lipid peroxidation as well as
hemolysis extent were evaluated. Protein peroxidation is one of the most serious
disturbances in oxidatively injured cells (35). We did not find any changes in the PP
level either after AHT or O3-AHT (9 sessions). Hemolysis, an index of erythrocyte
damage,
is thought to be the most critical deleterious effect of ozone on the blood cells (36).
There is evidence that the influence of ozone on erythrocytes is closely
dose-dependent.
Hemolysis during exposure to ozone in concentrations even up to 100 µg/ml is practically
negligible in the general population (37, 38). In the present study, we did not observe
the enhancement of erythrocyte damage either. The FHP level was stable after AHT and
O3-AHT (9 sessions) as compared to the baseline results. The lipid peroxidation is another
manifestation of oxidative cell injury. We measured concentration of the final products of
this process: malonaldehyde and 4- hydroxyalkenals (LPO) and found only a nonsignificant
increase LPO level after 9 sessions of O3-AHT. Giunta et al (39) observed a significant
increase in malonaldehyde level after O3-AHT. In contrast, other authors reported an
increase in LPO level only in the samples of blood directly exposed to ozone, i.e. taken
from the bottle (28). In conditions of oxidative stress derived from ozone
exposure,
interpretation of these results is a little difficult. Lipid oxidation products may
originate both from oxidatively injured cells as well as from the reaction between ozone
and PUFA incorporated in plasma lipoproteins; the process occurs in the bottle where blood
is exposed to ozone. Given these findings and the results on PP and FHP, discussed
previously, oxidative cell injury after exposure to ozone in the concentration of 50
µg/ml seems unlikely. A similar conclusion may be drawn analyzing the results from the
second part of study, where early changes in the parameters measured, immediately after
the first exposure to ozone were determined. Ozone dissolves in the blood almost
immediately. Free radicals disappear over several hours (37, 40). The changes in the
antioxidant system may also proceed very quickly (32). Based on these facts, the
evaluation of LPO, PP, FHP and GSH levels just after the first O3-AHT was
performed. No
significant changes were observed. GSH levels 20 minutes after the first O3-AHT procedure
did not differ compared to the concentrations found just before this session. No changes
in LPO and PP levels were found. No increase in FHP concentration was observed
either. In summary, this study demonstrated that O3-AHT with an ozone concentration of 50
µg/ml,
applied three times a week, did not induce oxidative cell injury in patients with ESRD on
maintenance HD. Nine sessions of O3-AHT caused, however, significant depletion in the GSH
level in erythrocytes, most possibly, associated with its increased consumption under
oxidative conditions. Nevertheless, the antioxidant defense system was able to protect the
cells against oxidative damaging processes. Thus, it may be concluded that O3-AHT is a
safe method and may be used as an adjunct medical approach in HD patients when oxidative
injury is considered. Given the present data showing a significant decrease in GSH level
and a little increment in lipid peroxidation extent, as well as the fact that a lower dose
of ozone (i.e. 35 µg/ml) may also provide beneficial clinical effects in HD patients
(reported previously (4)), one may recommend the use of ozone in doses a little lower than
those applied in the present study. The therapeutic doses defined for the general
population are somewhat high for HD patients who are under constant oxidative stress. To
achieve a who better adaptation of the organism to such therapy, beginning O3-AHT with
very low doses of ozone, and titration during following sessions up to the final dosage
may be advised. Antioxidant defense may be intensified by the administration of
acethylocysteine, precursor of glutathion, and by increasing vitamin C dosage
supplementation during O3-AHT.
ACKNOWLEDGEMENTS
This study was partially supported by the National Research Fund
(KBN) via
grant of Gdansk Medical University (ST-4).
REFERENCES
1. Bocci V. Biological and clinical effects of ozone. Has ozone therapy a
future in medicine? Br J Biomed Sci 1999; 56: 270-9.
2. Jungers P, Khoa TN, Massy ZA, et al. Incidence of atherosclerotic
arterial occlusive accidents in predialysis and dialysis patients: A multicentric study in
the Ile de France district. Nephrol Dial Transplant 1999; 14: 898-902.
3. Sroczynski J, Antoszewski Z, Matyszczyk B, et al. Clinical assessment
of treatment results for atherosclerotic ischemia of the lower extremities with
intraarterial ozone injections. Pol Tyg Lek 1992; 47: 964-6.
4. Tylicki L, Nieweglowski T, Biedunkiewicz B, Burakowski S, Rutkowski B.
Beneficial clinical effects of ozonated autohemotherapy in chronically dialysed patients
with atherosclerotic ischemia of the lower limbs pilot study. Int J Artif Organs
2001; 24: 79-82.
5. Koren H, Devlin R, Graham D, et al. Ozone-induced inflammation in the
lower airways of human subjects. Am Rev Respir Dis 1989; 139: 407-15.
6. Haugen E, Nath KA. The involvement of oxidative stress in the
progression of renal injury. Blood Purif 1999; 17: 58-65.
7. Iuliano L. The oxidant stress hypothesis of atherogenesis. Lipids 2001;
36 (suppl): S41-4.
8. Ueno I, Hoshino M, Miura T, Shinriki N. Ozone exposure generates free
radicals in the blood samples in vitro. Detection by the ESR spin-trapping
technique. Free Radic Res 1998; 29: 127-35.
9. Morena M, Cristol JP, Canaud B. Why hemodialysis patients are in a
prooxidant state? What could be done to correct the pro/antioxidant imbalance. Blood Purif
2000; 18: 191-9.
10. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid
peroxidation products: Malonaldehyde and 4- hydroxynonenal. Methods Enzymol 1990; 186:
407-21.
11. Anderson M. Enzymatic and chemical methods for the determination of
glutathione. In: Dolphin D, Poulson R, Avramovic O, eds. Glutathione: Chemical,
biochemical and medical aspects. John Wiley and Sons; 1989: pp. 339-65.
12. Garibaldi S, Aragno I, Odetti P, Marinari UM. Relationships between
protein carbonyls, retinol and tocopherols level in human plasma. Biochem Mol Biol Int
1994; 34: 729-36.
13. Watkins B, Bermes E. Measurements of plasma hemoglobin. In: Sunderman
F, ed. Seminar on biochemical hematology. Philadelphia: Institute for Clinical Science Inc
1979: pp. 57- 62.
14. Halliwell B, Cross CE. Oxygen-derived species: their relation to human
disease and environmental stress. Environ Health Perspect 1994; 102: 5-12.
15. Hasselwander O, Young IS. Oxidative stress in chronic renal
failure.
Free Radic Res 1998; 29: 1-11.
16. Girelli D, Olivieri O, Stanzial AM, et al. Low platelet glutathione
peroxidase activity and serum selenium concentration in patients with chronic renal
failure: Relations to dialysis treatments, diet and cardiovascular complications. Clin Sci
1993; 84: 611-7.
17. Ward RA, McLeish KR. Hemodialysis with cellulose membranes primes the
neutrophil oxidative burst. Artif Organs 1995; 19: 801-7.
18. Lonnemann G. The role of contaminated dialysate in
hemodialysis-associated cytokine production. Contrib Nephrol 1990; 86: 121-7.
19. Morena M, Cristol JP, Bosc JY, et al. Convective and diffusive losses
of vitamin C during haemodiafiltration session: A contributive factor to oxidative stress
in haemodialysis patients. Nephrol Dial Transplant 2002; 17: 422-7.
20. Koenig JS, Fischer M, Bulant E, Tiran B, Elmadfa I, Druml W.
Antioxidant status in patients on chronic hemodialysis therapy: Impact of parenteral
selenium supplementation. Wien Klin Wochenschr 1997; 109: 13-9.
21. United States Renal Data System: 1999 Annual Data Report. Am J Kidney
Dis 1999; 34 (suppl 1): S1-176.
22. Eckardt KU. Pathophysiology of renal anemia. Clin Nephrol 2000; 53
(suppl): S2-8.
23. Miyata T, Notoya K, Yoshida K, et al. Advanced glycation end products
enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and
in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 1997;
8: 260-70.
24. Boaz M, Green M, Fainauru M, Smetana S. Oxidative stress and
cardiovascular disease in hemodialysis. Clin Nephrol 2001; 55: 93-100.
25. Biedunkiewicz B, Tylicki L, Nieweglowski T, et al. Beneficial effects
of ozonated autohemotherapy in hemodialyzed patients with atherosclerotic ischemia lower
limbs (abstract). Nephrol Dial Transplant 2002; 17 (suppl 7): S260.
26. Rice-Evans C, Miller N. Total antioxidant status in plasma and body
fluids. New York: Academic Press Inc; 1994: pp. 279-93.
27. Pryor WA. Mechanisms of radical formation from reactions of
ozone with target molecules in the lung. Free Radic Biol Med 1994; 17:
451-65.
28. Hernandez F, Menendez S, Wong R. Decrease of blood cholesterol and
stimulation of antioxidative response in cardiopathy patients treated with endovenous
ozone therapy. Free Radic Biol Med 1995; 19: 115-9.
29. Freeman BA, Mudd JB. Reaction of ozone with sulfhydryls of human
erythrocytes. Arch Biochem Biophys 1981; 208: 212-20.
30. Shinriki N, Suzuki T, Takama K, et al. Susceptibilities of plasma
antioxidants and erythrocyte constituents to low levels of ozone. Haematologia 1998; 29:
229-39.
31. Bocci V, Luzzi E, Corradeschi F, et al. Studies on the biological
effects of ozone: 4. Cytokine production and glutathione levels in human
erythrocytes. J
Biol Regul Homeost Agents 1993; 7: 133-8.
32. Bocci V, Valacchi G, Corradeschi F, Fanetti G. Studies on the
biological effects of ozone: 8. Effects on the total antioxidant status and on
interleukin-8 production. Mediators Inflamm 1998; 7: 313-7.
33. Kubasova T, Horvath M, Kocsis K, Fenyo M. Effect of visible light on
some cellular and immune parameters. Immunol Cell Biol 1995; 73: 239-44.
34. Hashimoto H, Mio T, Sumino K. Lipid abnormalities of erythrocyte
membranes in hemodialysis patients with chronic renal failure. Clin Chim Acta 1996; 262:
137-45.
35. Cochrane CG. Mechanisms of oxidant injury of cells. Mol Aspects Med
1991; 12: 137-47.
36. Bocci V. Ozone as a bioregulator. Pharmacology and toxicology of
ozonetherapy today. J Biol Regul Homeost Agents 1996; 10: 31-53.
37. Bocci V, Valacchi G, Corradeschi F, et al. Studies on the biological
effects of ozone: 7. Generation of reactive oxygen species (ROS) after exposure of human
blood to ozone. J Biol Regul Homeost Agents 1998; 12: 67-75.
38. Zimran A, Wasser G, Forman L, Gelbart T, Beutler E. Effect of ozone on
red blood cell enzymes and intermediates. Acta Haematol 2000; 102: 148-51.
39. Giunta R, Coppola A, Luongo C, et al. Ozonized autohemotransfusion
improves hemorheological parameters and oxygen delivery to tissues in patients with
peripheral occlusive arterial disease. Ann Hematol 2001; 80: 745-8.
40. Goldstein BD, Balchum OJ, Demopoulos HB, Duke PS. Electron
paramagnetic resonance spectroscopy. Free radical signals associated with ozonization of
linoleic acid. Arch Environ Health 1968; 17: 46-9.
|